Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01973946 · ClinicalTrials.gov registry record · NA
Cancer Symptom Monitoring Telephone System With Nurse Practitioner (NP) Follow up
A NA study, sponsored by University of Utah.
- Completed
- Registry status
- NA
- Development phase
- 358
- Enrollment target
NCT01973946: Completed NA study, sponsored by University of Utah.
NCT01973946 is a NA study that has completed, run by University of Utah. The registered enrollment target is 358 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01973946, a NA study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- NA
- Development phase
- 358 participants
- Enrollment target
Study Summary
The purpose of this prospective trial is to test a daily telephone based automated symptom monitoring and response system to track and further treat unrelieved symptoms for patients living at home during chemotherapy treatment as compared with usual care which consists of patients calling their oncology provider for symptom concerns.
Primary Outcome
During daily automated calls, patients provided information about common chemotherapy symptoms on a 0-10 scale.
Interventions
- OTHER Symptom Alert and Coaching
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 358 participants |
| Start Date | 2007-09 |
| Est. Completion | 2012-04 |
| Phase | NA |
What the finished NCT01973946 record still lists
NCT01973946 is an interventional study that assigns participants to a tested intervention. The registered 358 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 1 intervention - of which Symptom Alert and Coaching is the first listed.
NCT01973946 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01973946 about?
NCT01973946 is a clinical study titled "Cancer Symptom Monitoring Telephone System With Nurse Practitioner (NP) Follow up". The purpose of this prospective trial is to test a daily telephone based automated symptom monitoring and response system to track and further treat unrelieved symptoms for patients living at home during chemotherapy treatment as compared with usual care which consists of patients calling their onco...
What is the current status of trial NCT01973946?
This trial is currently completed. It is a NA study. The enrollment target is 358 participants. The study started on 2007-09. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01973946?
The interventions under investigation include: Symptom Alert and Coaching (OTHER).
Who is sponsoring clinical trial NCT01973946?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01973946's enrollment target sits among peer trials
358 288th of 2000 higher than 1,712 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04373317 · 358 participants · Phase 4
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
- NCT05684965 · 358 participants · Phase 1
XTX301 in Patients With Advanced Solid Tumors
- NCT05824975 · 358 participants · Phase 1
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- NCT06480227 · 358 participants · NA
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia